DrugBank 6.0: the DrugBank Knowledgebase for 2024

Craig Knox, Mike Wilson, Christen M. Klinger, Mark Franklin, Eponine Oler(University of Alberta), Alexander E. Wilson, Allison Pon, Jordan J. Cox, Na Eun Chin, Seth A Strawbridge, Marysol García-Patiño, Ray Kruger(University of Alberta), Aadhavya Sivakumaran(University of Alberta), Selena Sanford(University of Alberta), Rahil Doshi(University of Alberta), Nitya Khetarpal(University of Alberta), Omolola Fatokun(University of Alberta), Daphnee Doucet(University of Alberta), Ashley Zubkowski(University of Alberta), Dorsa Yahya Rayat(University of Alberta), Hayley Jackson(University of Alberta), Karxena Harford(University of Alberta), Afia Anjum(University of Alberta), Mahi Zakir(University of Alberta), Fei Wang(University of Alberta), Siyang Tian(University of Alberta), Brian Lee(University of Alberta), Jaanus Liigand(University of Alberta), Harrison Peters(University of Alberta), Ruo Qi Wang, Tue Nguyen, Denise So, Matthew Sharp, Rodolfo da Silva, C. Gabriel, J.D. Scantlebury, Marissa Jasinski, David S. Ackerman, Timothy Jewison, Tanvir Sajed(University of Alberta), Vasuk Gautam(University of Alberta), David S. Wishart(University of Alberta)
Nucleic Acids Research
October 16, 2023
10.1093/nar/gkad976
Cited by 1,465Open Access
Full Text

Abstract

First released in 2006, DrugBank (https://go.drugbank.com) has grown to become the 'gold standard' knowledge resource for drug, drug-target and related pharmaceutical information. DrugBank is widely used across many diverse biomedical research and clinical applications, and averages more than 30 million views/year. Since its last update in 2018, we have been actively enhancing the quantity and quality of the drug data in this knowledgebase. In this latest release (DrugBank 6.0), the number of FDA approved drugs has grown from 2646 to 4563 (a 72% increase), the number of investigational drugs has grown from 3394 to 6231 (a 38% increase), the number of drug-drug interactions increased from 365 984 to 1 413 413 (a 300% increase), and the number of drug-food interactions expanded from 1195 to 2475 (a 200% increase). In addition to this notable expansion in database size, we have added thousands of new, colorful, richly annotated pathways depicting drug mechanisms and drug metabolism. Likewise, existing datasets have been significantly improved and expanded, by adding more information on drug indications, drug-drug interactions, drug-food interactions and many other relevant data types for 11 891 drugs. We have also added experimental and predicted MS/MS spectra, 1D/2D-NMR spectra, CCS (collision cross section), RT (retention time) and RI (retention index) data for 9464 of DrugBank's 11 710 small molecule drugs. These and other improvements should make DrugBank 6.0 even more useful to a much wider research audience ranging from medicinal chemists to metabolomics specialists to pharmacologists.

Related Papers

DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart, Yannick Djoumbou-Feunang, An Chi Guo et al.|Nucleic Acids Research|2017|8.7k
DrugBank: a comprehensive resource for in silico drug discovery and exploration
David S. Wishart|Nucleic Acids Research|2005|4k
HMDB 4.0: the human metabolome database for 2018
David S. Wishart, Yannick Djoumbou-Feunang, Ana Marcu et al.|Nucleic Acids Research|2017|3.5k
HMDB 5.0: the Human Metabolome Database for 2022
David S. Wishart, AnChi Guo, Eponine Oler et al.|Nucleic Acids Research|2021|2.4k
Advancing Drug Discovery via Artificial Intelligence
H. C. Stephen Chan, Hanbin Shan, Thamani Dahoun et al.|Trends in Pharmacological Sciences|2019|634